Neogenomics (NEO) Inventory (2010 - 2026)

Neogenomics has reported Inventory for 17 years, with the latest figure at $29.8 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory changed 0.22% year-over-year to $29.8 million; the trailing twelve-month figure through Mar 2026 stood at $29.8 million (changed 0.22% YoY), and the FY2025 full-year result was $28.6 million, up 6.8% from the prior year.
• Inventory for Q1 2026 stood at $29.8 million, up from $28.6 million in the prior quarter.
• The five-year high for Inventory was $34.2 million in Q2 2025, with the low at $20.3 million in Q1 2024.
• Historically, Inventory has averaged $25.7 million across 5 years, with a median of $24.4 million in 2023.
• Annual changes were most pronounced in 2024 — Inventory retreated 16.83% — and 2025, when it jumped 47.2%.
• Neogenomics' Inventory stood at $24.3 million in 2022, then dropped by 0.5% to $24.2 million in 2023, then climbed by 10.73% to $26.7 million in 2024, then grew by 6.8% to $28.6 million in 2025, then advanced by 4.45% to $29.8 million in 2026.
• The last three Inventory figures came in at $29.8 million (Q1 2026), $28.6 million (Q4 2025), and $28.5 million (Q3 2025), per Business Quant data.